234 related articles for article (PubMed ID: 23770046)
21. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway.
Lallemand-Breitenbach V; Jeanne M; Benhenda S; Nasr R; Lei M; Peres L; Zhou J; Zhu J; Raught B; de Thé H
Nat Cell Biol; 2008 May; 10(5):547-55. PubMed ID: 18408733
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer.
Jazaeri AA; Ferriss JS; Bryant JL; Dalton MS; Dutta A
Gynecol Oncol; 2010 Aug; 118(2):189-95. PubMed ID: 20462630
[TBL] [Abstract][Full Text] [Related]
23. EVI1 splice variants modulate functional responses in ovarian cancer cells.
Dutta P; Bui T; Bauckman KA; Keyomarsi K; Mills GB; Nanjundan M
Mol Oncol; 2013 Jun; 7(3):647-68. PubMed ID: 23517670
[TBL] [Abstract][Full Text] [Related]
24. Repression of E1AF transcriptional activity by sumoylation and PIASy.
Nishida T; Terashima M; Fukami K; Yamada Y
Biochem Biophys Res Commun; 2007 Aug; 360(1):226-32. PubMed ID: 17585876
[TBL] [Abstract][Full Text] [Related]
25. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer.
Nanjundan M; Nakayama Y; Cheng KW; Lahad J; Liu J; Lu K; Kuo WL; Smith-McCune K; Fishman D; Gray JW; Mills GB
Cancer Res; 2007 Apr; 67(7):3074-84. PubMed ID: 17409414
[TBL] [Abstract][Full Text] [Related]
26. HIF-1α SUMOylation affects the stability and transcriptional activity of HIF-1α in human lens epithelial cells.
Han X; Wang XL; Li Q; Dong XX; Zhang JS; Yan QC
Graefes Arch Clin Exp Ophthalmol; 2015 Aug; 253(8):1279-90. PubMed ID: 25877955
[TBL] [Abstract][Full Text] [Related]
27. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis.
Tanaka M; Suzuki HI; Shibahara J; Kunita A; Isagawa T; Yoshimi A; Kurokawa M; Miyazono K; Aburatani H; Ishikawa S; Fukayama M
Oncogene; 2014 May; 33(19):2454-63. PubMed ID: 23752186
[TBL] [Abstract][Full Text] [Related]
28. The novel arsenical Darinaparsin circumvents BRG1-dependent, HO-1-mediated cytoprotection in leukemic cells.
Garnier N; Petruccelli LA; Molina MF; Kourelis M; Kwan S; Diaz Z; Schipper HM; Gupta A; del Rincon SV; Mann KK; Miller WH
Leukemia; 2013 Nov; 27(11):2220-8. PubMed ID: 23426167
[TBL] [Abstract][Full Text] [Related]
29. Review: Aberrant EVI1 expression in acute myeloid leukaemia.
Hinai AA; Valk PJ
Br J Haematol; 2016 Mar; 172(6):870-8. PubMed ID: 26729571
[TBL] [Abstract][Full Text] [Related]
30. Physical and functional interaction of the proto-oncogene EVI1 and tumor suppressor gene HIC1 deregulates Bcl-xL mediated block in apoptosis.
Pradhan AK; Halder A; Chakraborty S
Int J Biochem Cell Biol; 2014 Aug; 53():320-8. PubMed ID: 24907396
[TBL] [Abstract][Full Text] [Related]
31. Potentiation of arsenic trioxide-induced apoptosis by 8-bromo-7-methoxychrysin in human leukemia cells involves depletion of intracellular reduced glutathione.
Xiao G; Tang X; Yao C; Wang C
Acta Biochim Biophys Sin (Shanghai); 2011 Sep; 43(9):712-21. PubMed ID: 21785114
[TBL] [Abstract][Full Text] [Related]
32. TG-interacting factor transcriptionally induced by AKT/FOXO3A is a negative regulator that antagonizes arsenic trioxide-induced cancer cell apoptosis.
Liu ZM; Tseng HY; Cheng YL; Yeh BW; Wu WJ; Huang HS
Toxicol Appl Pharmacol; 2015 May; 285(1):41-50. PubMed ID: 25791921
[TBL] [Abstract][Full Text] [Related]
33. Solubility shift and SUMOylaltion of promyelocytic leukemia (PML) protein in response to arsenic(III) and fate of the SUMOylated PML.
Hirano S; Tadano M; Kobayashi Y; Udagawa O; Kato A
Toxicol Appl Pharmacol; 2015 Sep; 287(3):191-201. PubMed ID: 26049103
[TBL] [Abstract][Full Text] [Related]
34. Autocrine human growth hormone increases sensitivity of mammary carcinoma cell to arsenic trioxide-induced apoptosis.
Zekri A; Ghaffari SH; Yousefi M; Ghanizadeh-Vesali S; Mojarrad M; Alimoghaddam K; Ghavamzadeh A
Mol Cell Endocrinol; 2013 Sep; 377(1-2):84-92. PubMed ID: 23851143
[TBL] [Abstract][Full Text] [Related]
35. Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma.
Zhang X; Yang XR; Sun C; Hu B; Sun YF; Huang XW; Wang Z; He YF; Zeng HY; Qiu SJ; Cao Y; Fan J; Zhou J
Cancer Lett; 2015 Sep; 366(1):112-22. PubMed ID: 26118777
[TBL] [Abstract][Full Text] [Related]
36. Manipulating PML SUMOylation via Silencing UBC9 and RNF4 Regulates Cardiac Fibrosis.
Liu Y; Zhao D; Qiu F; Zhang LL; Liu SK; Li YY; Liu MT; Wu D; Wang JX; Ding XQ; Liu YX; Dong CJ; Shao XQ; Yang BF; Chu WF
Mol Ther; 2017 Mar; 25(3):666-678. PubMed ID: 28143738
[TBL] [Abstract][Full Text] [Related]
37. ATL response to arsenic/interferon therapy is triggered by SUMO/PML/RNF4-dependent Tax degradation.
Dassouki Z; Sahin U; El Hajj H; Jollivet F; Kfoury Y; Lallemand-Breitenbach V; Hermine O; de Thé H; Bazarbachi A
Blood; 2015 Jan; 125(3):474-82. PubMed ID: 25395419
[TBL] [Abstract][Full Text] [Related]
38. Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells.
Liu ZM; Tseng JT; Hong DY; Huang HS
Biochem J; 2011 Sep; 438(2):349-58. PubMed ID: 21649584
[TBL] [Abstract][Full Text] [Related]
39. Ecotropic viral integration site 1, a novel oncogene in prostate cancer.
Queisser A; Hagedorn S; Wang H; Schaefer T; Konantz M; Alavi S; Deng M; Vogel W; von Mässenhausen A; Kristiansen G; Duensing S; Kirfel J; Lengerke C; Perner S
Oncogene; 2017 Mar; 36(11):1573-1584. PubMed ID: 27617580
[TBL] [Abstract][Full Text] [Related]
40. Transcription Factor hDREF Is a Novel SUMO E3 Ligase of Mi2α.
Yamashita D; Moriuchi T; Osumi T; Hirose F
J Biol Chem; 2016 May; 291(22):11619-34. PubMed ID: 27068747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
